James Enlou Tcheng
#165,258
Most Influential Person Now
James Enlou Tcheng's AcademicInfluence.com Rankings
James Enlou Tchengmedical Degrees
Medical
#3388
World Rank
#3856
Historical Rank
Cardiology
#355
World Rank
#366
Historical Rank
James Enlou Tchengphilosophy Degrees
Philosophy
#9704
World Rank
#13302
Historical Rank
Logic
#6673
World Rank
#8212
Historical Rank
Download Badge
Medical Philosophy
James Enlou Tcheng's Degrees
- Doctorate Medicine Harvard University
- PhD Cardiology Stanford University
Why Is James Enlou Tcheng Influential?
(Suggest an Edit or Addition)James Enlou Tcheng's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. (2002) (1310)
- Telehealth transformation: COVID-19 and the rise of virtual care (2020) (915)
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months (1994) (844)
- Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. (2005) (621)
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). (2015) (560)
- Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. (2005) (514)
- Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. (1994) (440)
- Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction (2003) (417)
- Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. (2007) (410)
- Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. (1998) (367)
- Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study (2001) (360)
- Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention (1997) (347)
- Restenosis after coronary angioplasty: an overview. (1991) (321)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. (2018) (285)
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention (1995) (271)
- Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial (2002) (264)
- Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. (1992) (259)
- Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. (1997) (255)
- Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. (2004) (254)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (2018) (248)
- Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). (2015) (243)
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). (2015) (235)
- Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. (1997) (227)
- Percutaneous revascularization of chronic coronary occlusions: an overview. (1995) (225)
- Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. (1995) (219)
- Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention (1999) (218)
- Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. (2001) (210)
- Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. (2004) (198)
- Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. (2005) (197)
- Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). (2002) (196)
- Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2005) (190)
- Relation between activated clotting time during angioplasty and abrupt closure. (1996) (188)
- Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. (2004) (187)
- Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. (1999) (162)
- Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2003) (161)
- Six‐Month Clinical and Angiographic Follow‐up After Direct Angioplasty for Acute Myocardial Infarction: Final Results From the Primary Angioplasty Registry (1994) (161)
- Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). (2007) (159)
- Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. (1996) (159)
- The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. (2006) (155)
- Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. (1998) (154)
- Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. (2005) (153)
- Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. (2002) (145)
- Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. (1992) (144)
- Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block (1998) (143)
- Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome (2000) (142)
- Double negatives. (2003) (139)
- Abciximab Readministration: Results of the ReoPro Readministration Registry (2001) (138)
- Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. (2006) (136)
- Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction: Results From the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2004) (135)
- Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. (2002) (132)
- Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. (1997) (131)
- Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. (2005) (127)
- Glycoprotein IIb/IIIa integrin blockade. (1998) (127)
- Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial (2002) (124)
- Coronary artery perforation during excimer laser coronary angioplasty. The percutaneous Excimer Laser Coronary Angioplasty Registry. (1993) (124)
- Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. (2000) (123)
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. (1994) (123)
- Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. (1998) (119)
- Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials (2003) (113)
- Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. (2006) (110)
- Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. (2004) (107)
- Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. (2003) (105)
- Interventional cardiac catheterization at Duke Medical Center. (1988) (104)
- Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function: The Intracoronary Eptifibatide (ICE) Trial (2010) (102)
- Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. (2003) (99)
- Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention (2001) (96)
- ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (2011) (93)
- Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. (2004) (93)
- Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries. (1994) (89)
- Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. (2004) (89)
- Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. (2003) (88)
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials (2015) (87)
- A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. (1998) (87)
- Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. (1998) (86)
- Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. (2000) (86)
- Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2010) (85)
- Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. (2000) (85)
- Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. (2004) (83)
- Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. (2005) (82)
- Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. (2009) (80)
- Usability evaluation of a personal health record. (2011) (78)
- Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). (2006) (78)
- Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty (1993) (76)
- Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide (1998) (73)
- Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). (2001) (71)
- Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. (2001) (70)
- Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry. (1994) (69)
- Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. (2006) (69)
- Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). (2003) (68)
- Intracoronary ultrasound evaluation of interventional technologies. (1991) (68)
- Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). (2004) (68)
- Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. (1994) (67)
- Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. (1999) (66)
- Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. (2005) (65)
- Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). (2012) (64)
- 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standar (2012) (63)
- Primary angioplasty in acute myocardial infarction (2002) (60)
- Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. (2002) (60)
- Long‐Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade with Percutaneous Coronary Intervention (1998) (58)
- Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention (2015) (57)
- Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. (2006) (57)
- Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. (2003) (57)
- Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. (2001) (57)
- Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. (2001) (56)
- Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). (2005) (56)
- Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. (2006) (55)
- Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. (2004) (51)
- Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. (2001) (51)
- Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. (2000) (47)
- Efficacy of abciximab readministration in coronary intervention. (2000) (46)
- Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. (2002) (45)
- Final results of the ReoPro readministration registry. (2004) (44)
- Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. (1995) (42)
- Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials (2014) (42)
- Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. (2007) (42)
- A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. (2003) (42)
- Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial (2003) (41)
- Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions (2012) (41)
- Development of a new technique for reducing pressure pulse generation during 308-nm excimer laser coronary angioplasty. (1995) (40)
- Saline infusion in excimer laser coronary angioplasty. (1996) (39)
- Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa (2002) (39)
- Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). (2004) (39)
- Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. (2004) (39)
- Outcome after prolonged balloon inflations of >20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty (1992) (38)
- Provisional stenting strategies: systematic overview and implications for clinical decision-making. (2000) (36)
- Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. (2002) (35)
- Readministration of abciximab: interim report of the ReoPro readministration registry. (1999) (35)
- Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. (2018) (35)
- Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). (2002) (34)
- Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. (1999) (34)
- Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. (2000) (34)
- Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina (2006) (33)
- An overview of the results of the EPIC trial. (1995) (32)
- Coronary artery stents: Evaluating new designs for contemporary percutaneous intervention (2002) (32)
- Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization: Results From the EPILOG Randomized Trial (2000) (32)
- Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. (2008) (32)
- ACC/AHA/SCAI 2014 health policy statement on structured reporting for the cardiac catheterization laboratory: a report of the American College of Cardiology Clinical Quality Committee. (2014) (30)
- Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. (2002) (30)
- The benefit of abciximab in percutaneous coronary revascularization is not device-specific. (2000) (30)
- Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty. (1995) (29)
- Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) experience. (1997) (28)
- ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. (2011) (28)
- Ultrasonographically guided manual compression of femoral artery injuries. (1995) (28)
- Creation of pseudo narrowing during coronary angioplasty. (1991) (27)
- Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. (1997) (27)
- Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. (2005) (26)
- Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. (1998) (26)
- Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris. (1991) (26)
- Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. (1993) (26)
- In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. (2002) (26)
- Treatment of long coronary artery narrowings with long angioplasty balloon catheters. (1993) (26)
- Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel (2005) (26)
- What's in a Name? The New ICD-10 (10th Revision of the International Statistical Classification of Diseases and Related Health Problems) Codes and Type 2 Myocardial Infarction. (2017) (26)
- Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial (2008) (25)
- Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. (1995) (24)
- Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. (2001) (24)
- Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. (2004) (24)
- Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. (2008) (23)
- ACC/AHA 2013 Methodology for Developing Clinical Data Standards: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (2014) (23)
- 711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization (1995) (22)
- HRS White Paper on interoperability of data from cardiovascular implantable electronic devices (CIEDs). (2019) (22)
- 711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization (1995) (22)
- Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. (2003) (22)
- Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate. (1992) (21)
- Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3) (1998) (21)
- Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. (2003) (21)
- Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. (2006) (21)
- Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial (1999) (20)
- Constructing the informatics and information technology foundations of a medical device evaluation system: a report from the FDA unique device identifier demonstration (2018) (20)
- A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial (2001) (19)
- Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans. (1992) (19)
- Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements. (2018) (19)
- Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire. (1998) (18)
- Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital. (2005) (18)
- Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials (2002) (18)
- Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association (2016) (18)
- Integrelin for emergency coronary artery stenting (1996) (17)
- Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). (2003) (17)
- ACC/AHA 2013 methodology for developing clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. (2014) (16)
- Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? (2003) (15)
- Translating the Translation: What Clinicians Should Know About the Fourth Universal Definition of Myocardial Infarction. (2018) (15)
- The natural history of single-vessel chronic coronary occlusion: a 25-year experience. (1997) (15)
- Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. (2007) (15)
- ACC/AHA/SCAI 2014 Health Policy Statement on Structured Reporting for the Cardiac Catheterization Laboratory: A Report of the American College of Cardiology Clinical Quality Committee (2014) (15)
- Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II (1996) (15)
- Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study. (2009) (15)
- Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial (2007) (14)
- Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). (2004) (14)
- Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. (2019) (14)
- Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial) (2003) (14)
- Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration. (2014) (14)
- Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. (1995) (14)
- Morbidity and Mortality Conference for Percutaneous Coronary Intervention (2017) (14)
- Novikoff hepatoma deoxyribonucleic acid polymerase. Sensitivity of the beta-polymerase to sulfhydryl blocking agents. (1976) (13)
- Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results. (2001) (13)
- Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents. (2013) (13)
- Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. (2007) (13)
- Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). (2004) (13)
- Multicenter registry of coronary atherectomy using the transluminal extraction-endarterectomy catheter (1990) (13)
- The changing profile of patient selection, procedural techniques, and outcomes in excimer laser coronary angioplasty. Participating Investigators of the Percutaneous Excimer Laser Coronary Angioplasty Registry. (1995) (12)
- Safety of readministration of abciximab; interim results of the ReoPro readministration registry (R3) (1998) (12)
- The duke multicenter coronary transluminal extraction-endarterectomy registry: Acute and chronic results (1991) (12)
- Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. (2003) (11)
- Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). (2010) (11)
- Stenting for acute myocardial infarction: The early United States multicenter experience (1996) (11)
- Effects of 308 nanometer excimer laser energy on 316 L stainless-steel stents: implications for laser atherectomy of in-stent restenosis. (2000) (11)
- Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry). (2005) (11)
- Section Review: Cardiovascular & Renal: Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors (1995) (10)
- Advancing medical device innovation through collaboration and coordination of structured data capture pilots: Report from the Medical Device Epidemiology Network (MDEpiNet) Specific, Measurable, Achievable, Results-Oriented, Time Bound (SMART) Think Tank. (2017) (10)
- 2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) and the American Society of Ec (2019) (10)
- Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). (2003) (10)
- Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. (2003) (9)
- Prasugrel: Clinical development and therapeutic application (2009) (9)
- Color Doppler sonographic appearance of patent needle tracts after femoral arterial catheterization. (1995) (9)
- Interventional Cardiac Catheterization at Duke Medical Center - The Duke Interventional Cardiac Catheterization Program (1988) (9)
- Maximal benefit of integrelin platelet IIB/IIIa blockade 6–24 hours after therapy: Results of the IMPACT-II trial (1996) (9)
- Prasugrel versus Clopidogrel Antiplatelet Therapy after Acute Coronary Syndrome (2012) (9)
- Artificial Intelligence and Machine Learning in Cardiology. (2019) (9)
- Acute myocardial infarction in a young male while playing paintball. (2002) (8)
- Systematic review of current natural language processing methods and applications in cardiology (2021) (8)
- Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes? (2001) (8)
- Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper (2021) (8)
- 2016 ACC/ASE/ASNC/HRS/SCAI Health Policy Statement on Integrating the Healthcare Enterprise. (2016) (7)
- ESPRIT in context: pharmacology matters! (2001) (7)
- Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. (1998) (7)
- Recanalization of chronic total coronary occlusions using a laser guide wire: The Eu and US total experience (1996) (7)
- Update on the American Board of Internal Medicine Maintenance of Certification Program: a report of the American College of Cardiology's Educational Quality Review Board. (2014) (7)
- Adjunctive abciximab to reperfusion therapy in patients with acute st-segment elevation myocardial infarction: A meta-analysis of randomized trials (2005) (7)
- A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting. (2004) (7)
- Economic Analysis of Centralized vs. Decentralized Electronic Data Capture in Multi-Center Clinical Studies (2011) (7)
- How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial (2003) (7)
- Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). (2003) (7)
- Anatomic propensity for restenosis following coronary angioplasty (1991) (7)
- Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet). (2016) (7)
- Platelet and Thrombin Inhibitors as Adjuncts to Thrombolytic Therapy and Percutaneous Coronary Interventions: A Review (1997) (7)
- Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial. (2005) (7)
- Quantitative and Qualitative Comparison of Text-Based and Graphical User Interfaces for Computerized Provider Order Entry (2006) (7)
- Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease: (2015) (7)
- Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. (1999) (7)
- Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery. (2013) (6)
- Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. (2004) (6)
- Research Management Team (RMT): A Model for Research Support ‐Services at Duke University (2012) (6)
- Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG? (2015) (6)
- Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents. (2000) (6)
- Registry Assessment of Peripheral Interventional Devices (RAPID) - Registry Assessment of Peripheral Interventional Devices Core Data Elements. (2018) (6)
- Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients (2016) (6)
- Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial (2008) (6)
- Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: Results from the IMPACT-II trial (1996) (6)
- Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. (1999) (6)
- The effect of diabetes on restenosis (1991) (5)
- Complementarity of stenting and abciximab for percutaneous coronary intervention (1998) (5)
- Eptifibatide in percutaneous coronary intervention. A review. (2002) (5)
- Erratum: Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC) (Journal of the American College of Cardiology (2015) 65:(931-41)) (2015) (5)
- Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. (1999) (5)
- A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. (1999) (5)
- Clinical outcome of “high-risk” vs “elective” patients undergoing percutaneous coronary intervention: Results from IMPACT-II (1996) (4)
- Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). (2003) (4)
- Safety issues surrounding use of platelet GP IIb/IIIa antagonists: Reversibility and readministration (1999) (4)
- Dosing and administration of ReoPro (c7E3 Fab). (1994) (4)
- Implementing a New Method for Activated Clotting Time:: Comparisons Between the Hemochron and the Actalyke-MaxACT Systems (2003) (4)
- Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. (2009) (4)
- From clinical pathways to CPOE: challenges and opportunities in standardization and computerization of postoperative orders for total joint replacement. (2006) (4)
- Coronary intervention and glycoprotein IIb/IIIa integrin blockade. (1999) (4)
- Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative (2020) (4)
- Current Multicentre Studies with the Excimer Laser: Design and Aims (2001) (4)
- Rebuttal: The CTO “No‐controversy” controversy: Should the field of CTO‐PCI be allowed to expand? (2012) (3)
- Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. (1998) (3)
- Primary Angioplasty (2018) (3)
- Magnitude and impact of after hours treatment delay in patients undergoing primary angioplasty for acute myocardial infarction: The CADILLAC Trial (2003) (3)
- Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Integrelin, a Platelet Aggregation Inhibitor (1996) (3)
- Outcome after prolonged balloon inflations of greater than 20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty. (1992) (3)
- Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art (2004) (2)
- Roadmap to a more useful and usable electronic health record (2021) (2)
- Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial (2001) (2)
- Achieving Data Liquidity: Lessons Learned from Analysis of 38 Clinical Registries (The Duke-Pew Data Interoperability Project) (2019) (2)
- Combined rotational and directional atherectomy guided by intravascular ultrasound in an occluded vein graft. (1992) (2)
- A47 Differences in endpoint identification by investigators versus independent review (1996) (2)
- Hemostasis of the femoral vasculature: Shouldn't we have an answer by now? (1999) (2)
- Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The cadillac trial (2003) (2)
- Vale, warfarin: a stentorian farewell. (1999) (2)
- LONG-TERM PROTECTION FROM MYOCARDIAL ISCHEMIC EVENTS IN A RANDOMIZED TRIALOF BRIEF INTEGRIN BETA 3 BLOCKADE WITH PERCUTANEOUS CORONARY INTERVENTION. COMMENTARY (1997) (2)
- A randomized study of 1276 patients undergoing PCI using lodixanol vs lopamidol ; comparison of in-hospital and 30 day major adverse cardiac events The results-of the VICC Trial (2003) (2)
- Assessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit. (2002) (2)
- 1002-82 Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction: The obesity paradox (2004) (2)
- SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention. (2020) (2)
- Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial (2002) (2)
- Effect of stent implantation and glycoprotein IIb/IIIa receptor blockade on target vessel revascularization in diabetics after primary PCI in acute myocardial infarction: the CADILLAC trial (2002) (2)
- Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. (2004) (2)
- The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. (1998) (2)
- Does myocardial damage or hemolysis occur during prolonged perfusion balloon angioplasty (1990) (2)
- After fibrinolysis: is cardiac catheterization the answer? (2006) (2)
- Eptifibatide in Coronary Intervention—The IMPACT Trials (1999) (1)
- Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention (1999) (1)
- Local delivery of heparin post‐PTCA: A multicenter randomized pilot study (2000) (1)
- Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction (2016) (1)
- Primary Coronary Intervention: The Technical Approach (2009) (1)
- ADDING DECISION SUPPORT TO COMPUTERIZED PROVIDER ORDER ENTRY IMPROVES VENOUS THROMBOEMBOLISM PROPHYLAXIS RATES (2009) (1)
- Primary PCI In St-Elevation Myocardial Infarction (2010) (1)
- Point-of-care measurement of platelet function before angioplasty strongly predicts future target vessel revascularization (2002) (1)
- 918-7 Limitations of Percutaneous Interventions in the Treatment of Bifurcation Lesions Involving the Left Anterior Descending Coronary Artery (1995) (1)
- "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. (2000) (1)
- Optimizing Patient Care through Clinical Decision Support: Identification of Opportunities and Call to Action by the National Academy of Medicine (2017) (1)
- Cardiac Safety Research Consortium (CSRC) (2015) (1)
- Patient Registries for Clinical Research (2019) (1)
- Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials (2003) (1)
- Drug-company sponsorship and the Declaration of Helsinki (2001) (1)
- Purification and properties of DNA polymerase-beta from guinea pig liver. (1978) (1)
- Abciximab readministration: Final results of the reoprofireadministration registry (2003) (1)
- Abciximab associated thrombocytopenia: evidence for a complex interaction with heparin (1998) (1)
- Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry (2003) (1)
- Eptifibatide in coronary intervention: past time for the next chapter. (2015) (1)
- Vascular access site complications during angioplasty with glycoprotein IIbIIIa receptor inhibition in the IMPACT II trial (1996) (1)
- Abstract Seventeenth annual meeting of the society for clinical trialP29 Prognostic significance of cardiac enzyme elevations detected through systematic screening in clinical trials (1996) (1)
- ACGME Interventional Cardiology Milestones 2.0–an overview: Endorsed by the Accreditation Council for Graduate Medical Education (2021) (1)
- Predictors of treatment delay in patients with acute myocardial infarction undergoing primary angioplasty: An analysis from the CADILLAC trial (2003) (1)
- Platelet llb/llla blockade with integrelin: Atherectomy patients (1996) (0)
- 801-3 Anemia worsens prognosis after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial (2004) (0)
- Relationship between time to treatment, electrocardiographic ST-segment resolution, and outcomes with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial (2003) (0)
- Eptifibatide in Coronary Intervention: The IMPACT and ESPRIT Trials (2003) (0)
- 869-2 Impact of intravenous beta-blockade during primary percutaneous intervention on convalescent left ventricular function (2004) (0)
- Unique device identifiers for coronary stent postmarket surveillance and research: A report from the Food and Drug Administration MedicalDeviceEpidemiologyNetworkUniqueDevice (2014) (0)
- Treatment of Acute Infarction With PCI Outcomes of Optimal or “ Stent-Like ” Balloon Angioplasty in Acute Myocardial Infarction : The CADILLAC Trial (2016) (0)
- Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients (2014) (0)
- (cadillac) trial abciximab and device investigation to lower late angioplasty complications primary percutaneous coronary intervention: Analysis from the controlled Impact of anemia in patients with acute myocardial infarction undergoing (2011) (0)
- The Duke databank interventional cardiology database (1991) (0)
- Safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes : Proceedings of a roundtable meeting, March 31, 1998, Atlanta, Georgia (1999) (0)
- Does abciximab and stenting improve outcomes in elderly patients undergoing primary PCI for acute myocardial infarction: data from the CADILLAC trial (2002) (0)
- Primary PCI in ST elevation myocardial infarction : Perspectives (2010) (0)
- Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. (2009) (0)
- Clinical implications of vulnerable plaque. (2006) (0)
- Which is the true channel? (2004) (0)
- CRT-200.53 Which Reperfusion Therapy Is Better in Patients with ST-Segment Elevation Myocardial Infarction within 3 Hours of the Onset of Symptoms? From Korea Acute Myocardial Infarction Registry (KAMIR) (2016) (0)
- Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial (2003) (0)
- 1004-53 Adjunctive pharmacotherapy during higher risk percutaneous coronary intervention: Eptifibatide-based antiplatelet therapy accompanied by only limited, specific antithrombin therapy (2004) (0)
- mpact of Anemia in Patients With cute Myocardial Infarction Undergoing rimary Percutaneous Coronary Intervention nalysis From the Controlled Abciximab and Device (2016) (0)
- 738–3 Long-term Survival with a Chronic Total Coronary Occlusion: A Comparison of Medical Therapy versus Angloplasty in Patients with Single Vessel Disease (1995) (0)
- Erratum: Update on the American Board of Internal Medicine Maintenance of Certification Program: A Report of the American College of Cardiologys Educational Quality Review Board (Journal of the American College of Cardiology (2014) 63 (92-100)) (2014) (0)
- Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. (2006) (0)
- Predictors and sequalae of subacute thrombosis after percutaneous intervention in acute myocardial infarction: The CADILLAC trial (2003) (0)
- Registry Assessment of Peripheral Interventional Devices Objective Performance Goals for Superficial Femoral and Popliteal Artery Peripheral Vascular Interventions. (2020) (0)
- Limitations of balloon angioplasty: Possible causes of restenosis (1988) (0)
- Abciximab with reduced heparin dosing during coronary intervention Final results of the EPILOG trial (1997) (0)
- Hospital percutaneous coronary intervention volume and outcome: does it matter? (2005) (0)
- Does optimal or stent-like PTCA provide equivalent outcomes compared to primary stenting in acute myocardial infarction? Early and late results from the CADILLAC trial (2002) (0)
- Update on Thrombolysis and Reperfusion in the Management of Acute ST Elevation MI (2002) (0)
- Abstract 9622: Baseline Hemodynamics with Cardiac Performance Response to Contrast Media During Diagnostic Cardiac Catheterization Enhances Prediction of Adverse Events in Heart Failure Patients (2011) (0)
- Does stenting benefit patients with left anterior descending infarction? Results from the CADILLAC trial (2002) (0)
- Key references: Antiplatelet therapy as an adjunct to thrombolysis and coronary angioplasty (2005) (0)
- DAMAGE TO POLYMER SURFACE AND DETACHMENT OF POLYMER FRAGMENTS DURING DELIVERY BALLOON EXPANSION OF DRUG-ELUTING STENTS: A PREVIOUSLY UNRECOGNIZED SOURCE FOR ADVERSE OUTCOMES (2012) (0)
- Abstract 14529: Management of Acute Myocardial Infarction in a Patient With a Left Ventricular Assist Device (2020) (0)
- No jacket required. (2001) (0)
- TCT CONNECT-187 Characteristics Associated With Reduced Patient Radiation Dose in an Academic Cardiac Catheterization Lab (2020) (0)
- mpact of Diabetes Mellitus on Myocardial erfusion After Primary Angioplasty n Patients With Acute Myocardial Infarction (2016) (0)
- TWO YEAR EXPERIENCE WITH HIGH-SENSITIVITY TROPONIN TESTING:INTERPRETATIVE VALUES FOR IMPROVING PATIENT DISPOSITION (2022) (0)
- Outcomes in patients requiring bail-out abciximab during primary intervention in acute myocardial infarction: Analysis from the CADILLAC trial (2003) (0)
- Marked mortality risk of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction (2003) (0)
- Abstract 1762: Relationship Between Leucocyte Count, Myonecrosis, Myocardial Perfusion and Outcomes Following Primary Angioplasty (2006) (0)
- Anti-thrombotic management in interventional cardiology (2006) (0)
- Percutaneous Coronary Intervention for Acute Myocardial Infarction Prognostic Implications of Creatine Kinase Elevation After Primary (2011) (0)
- The new platelet inhibitors in coronary intervention (1996) (0)
- Abstract 920: Is Balloon Angioplasty without Stent Placement Adequate for Patients in Whom Early Coronary Artery Bypass Surgery Is Planned after Primary Percutaneous Coronary Intervention? (2008) (0)
- mpact of Intravenous Beta-Blockade efore Primary Angioplasty on Survival n Patients Undergoing Mechanical eperfusion Therapy for Acute Myocardial Infarction (2016) (0)
- [Laser coronary angioplasty. Critical analysis of the first patients]. (1994) (0)
- ST-segment elevation resolution as a predictor of mortality in patients with thrombolysis in myocardial infarction III flow in the infarct artery after primary angioplasty: The CADILLAC trial (2003) (0)
- 1061-100 Predictors of reinfarction after ST elevation myocardial infarction and glycoprotein receptor blockade: Analysis from the CADILLAC trial (2004) (0)
- CRT-200.52 Dynamic Regulation of Aggregate Formation and Stability in Response to Platelet Inhibition Via GP 2b-3a vs. P2Y12 (2016) (0)
- Prognostic value of the absolute degree of ST-segment elevation of the ECG at baseline and after primary angioplasty: Analysis from the CADILLAC trial (2003) (0)
- Percutaneous excimer laser coronary angioplasty: development of technology and initial clinical results (1992) (0)
- Platelet Glycoprotein llb/llla (2018) (0)
- Elements of CPOE Style: A Guide to Formatting Text for Clinician Users (2007) (0)
- Abstract 323: Standardized Triggers for Catheterization Laboratory Morbidity and Mortality Case Review (2015) (0)
- Elevated troponin following percutaneous coronary intervention predicts subsequent events: results from the ESPRIT trial (2002) (0)
- Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide (2016) (0)
- Coronary artery bypass grafting versus percutaneous coronary intervention for left main disease in chronic kidney disease patients: a meta-analysis (2020) (0)
- New international technology: The autoperfusion balloon catheter (1988) (0)
- CURRENT LANDSCAPE OF HYBRID REVASCULARIZATIONS: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY (2018) (0)
- P71 Impact of the clinical events committee process on data safety monitoring (1996) (0)
- CRT-500 Invasive Catheterization Case Length Analysis: Results from Duke University Medical Center (2015) (0)
- 760-2 Angiographic Outcome After “Cutting” Balloon Angioplasty (1995) (0)
- Electronic health data quality maturity model for medical device evaluations (2020) (0)
- GP IIb/IIIa blockade in elective percutaneous coronary intervention. (2004) (0)
- Appendix Participating Institutions , Principal Investigators , and Study Coordinators (2001) (0)
- Treatment of Palmaz-Schatz In-stent Restenosis: 6–Month Clinical Follow-up (2000) (0)
- Pursuit of the Optimal Antithrombotic Regimen for Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Who Undergo Subsequent Percutaneous Coronary Intervention. (2019) (0)
- Small-Molecule Glycoprotein IIb/IIIa Inhibitors as Adjunctive Therapy in Percutaneous Coronary Interventions (2000) (0)
- Meta-analysis of Randomized Trials Acute ST-Segment Elevation Myocardial Infarction : A Abciximab as Adjunctive Therapy to Reperfusion in Correction (2005) (0)
- P-294BENEFIT OF COMPUTERIZED TOMOGRAPHY SCAN WITH INTRAVENOUS CONTRAST PRIOR TO OESOPHAGECTOMY IN PATIENTS WITH OESOPHAGEAL CANCER (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With James Enlou Tcheng?
James Enlou Tcheng is affiliated with the following schools:
